Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Ventana and Biocare Medical sign license agreement for diagnosis of prostate lesions

March 1, 2013

Mirabegron launched in the U.K. for treatment of overactive bladder

Feb. 26, 2013

Purdue Pharma prepares new TRPV1 antagonists

Feb. 26, 2013

Relypsa enrolls first patient in pivotal phase III patiromer trial

Feb. 22, 2013

Encouraging immunogenicity results reported from phase III program for NX-1207

Feb. 20, 2013

Galenica provides update on regulatory processes for PA-21

Feb. 12, 2013

ALK5 and/or ALK4 inhibitors developed at SK Chemicals

Feb. 6, 2013

EC approves BindRen for hyperphosphatemia

Jan. 29, 2013

Zerenex meets primary and secondary endpoints in phase III trial

Jan. 29, 2013

First patient treated in GCS-100 phase I/II trial

Jan. 29, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...